Are these 3 ASX shares the next biotech blockbusters?

One of my favourite companies on the ASX would have to be biotech giant CSL Limited (ASX: CSL).

Thanks largely to its successful immunoglobulin business, CSL has grown into a $60 billion industry behemoth in the last decade.

Three shares which are aiming to follow in CSL’s footsteps are listed below. Could they be future biotech stars?

Bionomics Ltd (ASX: BNO)

Last year this fledgling biotech company released positive Phase II trial results of its BNC210 anxiety drug. BNC210 not only outperformed the current standard of care, but also exhibited no signs of sedation, memory impairment, addiction, or loss of motor co-ordination. Management has forecast the global therapeutic market for the treatment of anxiety to be worth US$18.2 billion by 2020. If BNC210 can one day become the standard of care for anxiety treatment then Bionomics will profit greatly. But there is still a lot of hard work to come before that is potentially a reality.

Cynata Therapeutics Ltd (ASX: CYP)

Another exciting biotech company I think is worth taking a closer look at is stem cell and regenerative medicine company Cynata. The company’s impressive Cymerus technology is able to produce an unlimited number of high quality stem cells at a low cost. These stem cells can then be used to treat numerous diseases including Graft versus Host Disease (GvHD) and cardiovascular disease. Major shareholder FUJIFILM has an exclusive worldwide license to market and sell its therapeutic MSC product CYP-001 for the treatment of GvHD.

Opthea Ltd (ASX: OPT)

Earlier this year Opthea released positive results from the Phase 1/2A clinical trial of its novel therapy OPT-302. The wet age-related macular degeneration therapy showed clinical activity in all patient groups investigated, including naïve and prior-treated patients. Another positive was that the strong result allowed the company to raise $42 million at a significant premium. This puts Opthea in a strong position to expand the clinical development of the potentially lucrative therapy. There is still a long way to go, but Opthea is a company I’ll be keeping a close eye on.

Whilst it may be a touch soon to invest in some of these biotech shares, I do think that these fast-growing blue-chip shares are in the buy zone today.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks means stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.

The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.